Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonafexor safety and proof-of-concept in Alport syndrome at risk of progression
2023-509638-20-00Phase 2Completed
- Sponsor
- ENYO Pharma
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of vonafexor in Alport syndrome, sponsored by ENYO Pharma. Primary endpoints: Number of Treatment-Emergent Adverse Events (TEAEs) and Change in physical examinations, vital signs, laboratory variables and lipid profile. Started Sep 2024; status: completed.
02
Drugs
vonafexor
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on 2023-509638-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509638-20-00.